Compare Davita Inc (DVA) vs iShares MSCI South Africa ETF (EZA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs iShares MSCI South Africa ETF — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while iShares MSCI South Africa ETF trades at $63.8 (market cap $455.34M). The key difference: Davita Inc is far larger — about 24.8× iShares MSCI South Africa ETF's market cap, and Davita Inc is trading nearer its 52-week high, iShares MSCI South Africa ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and iShares MSCI South Africa ETF for 70 Days on average.
| DVA | EZA | |
|---|---|---|
Market Cap | $11.29B | $455.34M |
Volume | 582,204 | 148,692 |
Sector | Health | Broad Market / Factor |
52-Week High | $240.96 | $81.60 |
52-Week Low | $103.87 | $60.43 |
Typical Hold Time | 114 Days | 70 Days |
Enterprise Value | $24.01B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 32.36% gross margins and 635.3% ROE, though net income margin declined to 5.47% in 2025. Recent partnership expansions with Humana for value-based kidney care and institutional buying by BlackRock provide positive catalysts. Valuation appears reasonable with P/E of 15 and P/S of 0.88, below sector averages.
Outlook remains mixed with analyst consensus target of $235.67 suggesting 33% upside, but technical indicators signal near-term caution. Key risks include regulatory pressures on healthcare reimbursements and rising debt-to-asset ratio reaching 65.55%. Earnings momentum from three consecutive quarterly beats supports fundamental strength, though margin compression warrants monitoring.
EZA trades at $63.8, up 2.42% today, but technical indicators signal a bearish trend with moving averages and oscillators in sell territory. The stock faces resistance near $64 and support at $61. Recent news highlights a brief price surge above the 50-day moving average in September but ongoing macroeconomic pressures from South Africa's exposure to commodities and financials.
The outlook remains cautious due to global reflation and high capital costs weighing on EZA's holdings. Risks include commodity price volatility and interest rate sensitivity, while potential upside hinges on stabilization in South African markets. Investors should weigh the ETF's concentrated exposures against broader emerging market uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About iShares MSCI South Africa ETF
EZA is a country-specific ETF that tracks the South African equity market. It provides exposure to large and mid-cap companies across key sectors like materials and financials, with top holdings such as AngloGold Ashanti and Naspers.
Read more on EZA →
